Abstract
MicroRNAs (miRNAs) are endogenously expressed and evolutionarily conserved small non-coding RNAs, which regulate gene expression. Several studies have shown that they are involved in fundamental biological processes, such as proliferation and apoptosis. MicroRNA dysregulation plays an important role in cancer onset and progression where miRs can function as both tumor promoters (oncomiRs) or tumor suppressors by targeting numerous biomolecules that are important in carcinogenesis. MicroRNA molecules are already entering the clinic as diagnostic and prognostic biomarkers for patient stratification and also as therapeutic targets and agents. Their role as biomarkers and therapeutic targets is appealing but several obstacles have as yet limited our ability to translate this potential into a clinical reality. This review provides a comprehensive overview of miRNAs with established functional relevance in cancer. Furthermore, approaches towards therapeutic miRNA-based intervention are discussed. Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs and strategies for the inhibition of oncogenic miRNAs.
Current Pharmaceutical Design
Title:microRNAs as Anti-Cancer Therapy
Volume: 20 Issue: 33
Author(s): Michela Garofalo, Gianpiero Di Leva and Carlo M. Croce
Affiliation:
Abstract: MicroRNAs (miRNAs) are endogenously expressed and evolutionarily conserved small non-coding RNAs, which regulate gene expression. Several studies have shown that they are involved in fundamental biological processes, such as proliferation and apoptosis. MicroRNA dysregulation plays an important role in cancer onset and progression where miRs can function as both tumor promoters (oncomiRs) or tumor suppressors by targeting numerous biomolecules that are important in carcinogenesis. MicroRNA molecules are already entering the clinic as diagnostic and prognostic biomarkers for patient stratification and also as therapeutic targets and agents. Their role as biomarkers and therapeutic targets is appealing but several obstacles have as yet limited our ability to translate this potential into a clinical reality. This review provides a comprehensive overview of miRNAs with established functional relevance in cancer. Furthermore, approaches towards therapeutic miRNA-based intervention are discussed. Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs and strategies for the inhibition of oncogenic miRNAs.
Export Options
About this article
Cite this article as:
Garofalo Michela, Leva Di Gianpiero and Croce M. Carlo, microRNAs as Anti-Cancer Therapy, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128211346
DOI https://dx.doi.org/10.2174/1381612820666140128211346 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry PET/CT Dose Planning for Volumetric Modulated arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer Patients
Current Radiopharmaceuticals Advances in the Knowledge and Clinical Applications of Lactic Acid Bacteria as Probiotics in the Urogenital Tract
Current Women`s Health Reviews Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Current Pharmaceutical Design Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry Sample Preparation Techniques for Mass Spectrometry in Proteomics Using Recently Developed Highly Selective Materials
Current Proteomics The Role of Cytochrome P450 in Cytotoxic Bioactivation: Future Therapeutic Directions
Current Cancer Drug Targets Study of drug-drug combinations based on molecular descriptors and physicochemical properties
Combinatorial Chemistry & High Throughput Screening Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets